Hospital Saint-Louis in Paris has expanded its partnership with Switzerland-based software company Sophia Genetics.

This partnership will see the hospital deploy the SOPHiA DDM Platform to enhance its research on Myeloid Disorders, particularly Myeloproliferative neoplasms (MPNs).

The hospital’s Cellular Biology Department, which is focused on in-depth clinical research to offer comprehensive care for MPN patients, aims to expedite research through the platform’s streamlined workflows.

This Cloud-native solution enables tailored next-generation sequencing workflows, providing quality, reproducible data to researchers on current gene panels.

It claims to help researchers understand the precise characterisation of the complex mutational landscape associated with myeloid neoplasms.

Hôpital Saint-Louis Molecular Diagnostics researcher Bruno Cassinat said: “While the providers and researchers in my department have decades of experience with MPNs and are well-versed in providing the highest quality care to our patients, we have been pleased with the support of the innovative technology that SOPHiA GENETICS offers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“The SOPHiA DDM Platform has been an essential tool to support us in streamlining our bioinformatics workflows, expediting our research, and making data-driven decisions for our patient population.”

The platform leverages artificial intelligence (AI) to efficiently analyse and interpret complex NGS data, thereby providing researchers with streamlined insights more quickly to help provide recommendations that are backed by data to patients.

SOPHiA GENETICS EMEA managing director Kevin Puylaert said: “As we continue expanding the use of data-driven medicine around the world, we are keenly focused on aiding hospitals and labs with their efforts to keep up with expanding international recommendations and the near-constant progress being made in targeted therapies for myeloid disorders.

“The SOPHiA DDM Platform is designed to ensure our customers not only have access to NGS workflows, but have the tools they need to identify insights that will help guide research, accelerate studies, and inform decision-making.”

Hôpital Saint-Louis has been a referral centre for over 50 years.

Last month, a regional and university hospital in France CHU de Nîmes expanded its collaboration with SOPHiA GENETICS to use the SOPHiA DDM Platform for pharmacogenomics research.